Page last updated: 2024-11-05

thalidomide and Lip Diseases

thalidomide has been researched along with Lip Diseases in 2 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Lip Diseases: Diseases involving the LIP.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lee, FC1
Hegarty, A1
Hodgson, T1
Porter, S1

Other Studies

2 other studies available for thalidomide and Lip Diseases

ArticleYear
Longterm clinical remission of oral and cutaneous pemphigus with thalidomide.
    International journal of dermatology, 2011, Volume: 50, Issue:9

    Topics: Female; Humans; Immunosuppressive Agents; Lip Diseases; Middle Aged; Mouth Diseases; Pemphigus; Thal

2011
Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2003, Volume: 95, Issue:5

    Topics: Adolescent; Child; Crohn Disease; Female; Follow-Up Studies; Granuloma; Humans; Immunosuppressive Ag

2003